Galderma’s stock dropped sharply after the U.S. Food and Drug Administration declined to approve Relfydess, the Swiss beauty giant’s injectable treatment designed to compete directly with AbbVie’s Botox. The decision, announced in late June, halts what was expected to be one of the most significant product launches in the neuromodulator category, a market valued at over $5 billion annually in the United States alone.
The FDA’s complete response letter raised questions about the clinical data package Galderma submitted, though the company has not disclosed the specific deficiencies cited by the regulator. Analysts had projected peak annual sales of $400 million to $600 million for Relfydess, making the rejection a meaningful setback for Galderma’s ambition to challenge Botox’s decades-long dominance in the aesthetic injectables space.
The ruling arrives amid heightened regulatory scrutiny of the beauty and wellness sector. The FDA has signaled a more cautious approach to neuromodulator approvals under the current administration, and Galderma’s rejection may reflect that broader tightening. For a company that went public in 2024 and has positioned itself as the pure-play leader in medical aesthetics, the timing could not be worse.
The company has indicated it will work with the FDA to address the concerns and resubmit. In the meantime, the neuromodulator market remains essentially a two-player game between Botox and Evolus’s Jeuveau, with Galderma watching from the sidelines.
Galderma’s portfolio still includes Dysport, its existing neuromodulator, and a robust pipeline of biostimulators and skincare products. But the Relfydess rejection removes a key growth vector from the company’s near-term narrative. The stock decline reflects not just the lost revenue opportunity but the signal that Galderma’s regulatory strategy may need recalibration.
